Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 14/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31384842 | 0.91 | XIAP (0.40) | XIAPBIRC2BIRC3CASP1CTSL | |
| SCHEMBL1300499 | 0.88 | XIAP (0.41) | XIAPBIRC2CASP1CTSLCTSB | |
| SCHEMBL1300495 | 0.88 | XIAP (0.41) | XIAPBIRC2CASP1CTSLCTSB | |
| SCHEMBL1300491 | 0.88 | XIAP (0.41) | XIAPBIRC2CASP1CTSLCTSB | |
| SCHEMBL1300496 | 0.88 | XIAP (0.41) | XIAPBIRC2CASP1CTSLCTSB | |
| SCHEMBL31384893 | 0.88 | XIAP (0.39) | XIAPBIRC2BIRC3CASP1CTSL | |
| SCHEMBL31384849 | 0.85 | CASP1 (0.48) | XIAPBIRC2BIRC3CASP1CTSL | |
| SCHEMBL12109045 | 0.84 | CTSK (0.39) | XIAPBIRC2CTSLCTSBCTSS | |
| SCHEMBL29922199 | 0.80 | ACE (0.41) | XIAPBIRC2CTSLCTSBCTSS | |
| SCHEMBL9973467 | 0.80 | CASP1 (0.49) | XIAPBIRC2BIRC3CASP1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061058-A1 | NOVEL COMPOUNDS AS IAP ANTAGONISTS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-03-27 | — | — | WO | disclosed |